ADVERSE EFFECTS OF SGLT2 INHIBITORS - A LITERATURE REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5231Keywords:
SGLT2 Inhibitors, Adverse Effects, Diabetic Ketoacidosis, Genitourinary Infections, Hypotension, Type 2 Diabetes MellitusAbstract
Introduction: Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors have rapidly become foundational in the management of type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and heart failure (HF), offering robust glycemic control and cardioprotective and renoprotective benefits. However, despite their favorable efficacy profile, clinicians must recognize and monitor for known adverse events associated with this drug class.
Aim of the study: The aim of this study was to systematically analyze and synthesize current evidence regarding the adverse effects associated with sodium–glucose cotransporter 2 (SGLT2) inhibitors. Particular emphasis was placed on identifying the most frequently reported complications, evaluating their underlying mechanisms, and assessing their clinical relevance in various patient populations. The study also sought to determine potential risk factors predisposing patients to these adverse outcomes and to discuss implications for clinical practice.
Material and methods: This study was designed as a review of the available literature. A structured search of biomedical databases was undertaken to identify peer-reviewed publications addressing adverse effects associated with SGLT2 inhibitors. Eligible sources included original research articles, randomized controlled trials, meta-analyses, and systematic reviews. Studies were selected according to their relevance and scientific rigor. Extracted data focused on the frequency, mechanisms, and clinical implications of reported adverse events. The collected evidence was synthesized descriptively to present a comprehensive overview of the safety profile of this therapeutic class.
Results and Conclusions: Common complications include genitourinary infections, especially genital mycotic infections, which are consistently reported across studies, and urinary tract infections, though the latter’s magnitude of risk may vary by agent and population subgroup. Meta‑analyses suggest increased risks of diabetic ketoacidosis, particularly in its euglycemic form, and osmotic diuresis‑related events such as volume depletion and hypotension. Serious but rare events identified in pharmacovigilance data include limb amputations. While SGLT2 inhibitors may not significantly elevate overall serious adverse event incidence in controlled settings, the risk profile requires careful patient selection and monitoring. SGLT2 inhibitors retain an overall favorable benefit–risk balance when used appropriately. Nevertheless, clinicians should maintain vigilance for specific complications—especially genitourinary infections and metabolic disturbances—and tailor therapy with risk stratification and preventive strategies. Continued surveillance and research are warranted to optimize long‑term safety.
References
Liang, I. C., Chang, H. H., Lai, Y. J., Chan, C. M., Sung, C. H., Pu, C. M., Chang, D. C., Ho, C. C., & Hung, C. F. (2025). Update on the efficacy and safety of sodium-glucose co-transporter 2 inhibitors in patients with chronic diseases: A systematic review and meta-analysis. Medicina, 61(2), 202. https://doi.org/10.3390/medicina61020202
Alrasheed, R. R., Altaf, A. F., Althurwi, A. H., Alrodan, S. F., Asiri, M. H., Alsaluli, B. A., Alsurur, M. A., Alghamdi, K. A., Alrowaithi, A. A., & Almalki, N. S. (2025). Heart failure outcomes with SGLT2 inhibitors in adults with type 2 diabetes: A systematic review and meta-analysis. Medicina, 62(1), 69. https://doi.org/10.3390/medicina62010069
Bhanushali, K. B., Asnani, H. K., Nair, A., Ganatra, S., & Dani, S. S. (2024). Pharmacovigilance study for SGLT2 inhibitors: Safety review of real-world data and randomized clinical trials. Current Problems in Cardiology, 49(9), 102664. https://doi.org/10.1016/j.cpcardiol.2024.102664
Pishdad, R., Auwaerter, P. G., & Kalyani, R. R. (2024). Diabetes, SGLT-2 inhibitors, and urinary tract infection: A review. Current Diabetes Reports, 24(5), 108–117. https://doi.org/10.1007/s11892-024-01537-3
Iordan, L., Avram, V. F., Timar, B., Sturza, A., Popescu, S., Albai, O., & Timar, R. Z. (2024). Safety of SGLT2 inhibitors and urinary tract infections in clinical practice: A cross-sectional study. Medicina, 60(12), 1974. https://doi.org/10.3390/medicina60121974
Jeon, B. J., Ko, Y. J., Park, J. Y., Bae, J. H., & Tae, B. S. (2025). Correlating urinary tract infection risks with sodium-glucose cotransporter-2 inhibitors: Insights from the National Health Insurance Data of Korea. Journal of Korean Medical Science, 40(38), e244. https://doi.org/10.3346/jkms.2025.40.e244
Lee, D., Seo, G., Kim, Y., Min, J. Y., & Yee, J. (2025). Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 27(10), 5805–5811. https://doi.org/10.1111/dom.16635
Colacci, M., Fralick, J., Odutayo, A., & Fralick, M. (2022). Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: A systematic review and meta-analysis. Canadian Journal of Diabetes, 46(1), 10–15.e2. https://doi.org/10.1016/j.jcjd.2021.04.006
Ajabnoor, A. M. (2026). Amputation and gangrene associated with SGLT2 inhibitors: Pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Journal of Endocrinological Investigation. Advance online publication. https://doi.org/10.1007/s40618-026-02809-3
Goldman, A., Fishman, B., Twig, G., Raschi, E., Cukierman-Yaffe, T., Moshkovits, Y., Pomerantz, A., Ben-Zvi, I., Dankner, R., & Maor, E. (2023). The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥75 years): A retrospective, pharmacovigilance study. Cardiovascular Diabetology, 22(1), 16. https://doi.org/10.1186/s12933-023-01743-5
Vallon, V. (2024). State-of-the-art review: Mechanisms of action of SGLT2 inhibitors and clinical implications. American Journal of Hypertension, 37(11), 841–852. https://doi.org/10.1093/ajh/hpae092
Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel-Rahman, E. M., & Awad, A. S. (2024). SGLT2 inhibitors: Beyond glycemic control. Journal of Clinical & Translational Endocrinology, 35, 100335. https://doi.org/10.1016/j.jcte.2024.100335
McLean, P., Bennett, J., Woods, E. T., et al. (2025). SGLT2 inhibitors across various patient populations in the era of precision medicine: The multidisciplinary team approach. npj Metabolic Health and Disease, 3, 29. https://doi.org/10.1038/s44324-025-00068-z
Joher, I., Singla, S., Shakeel Ahmed, U., Singla, B., Amir, S., Mastoi, M. G., Kumawat, S., Khalid, R., Choudhry, F., Rahat, S. A. A., & Iqbal, A. (2025). Sodium-glucose cotransporter-2 (SGLT2) inhibitors and risk of heart failure hospitalization in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Cureus, 17(11), e96456. https://doi.org/10.7759/cureus.96456
An, Y., & Zhang, H. (2026). SGLT-2 inhibitors: A deeper dive into their renal protective properties beyond glycemic control and proteinuria reduction. American Journal of Nephrology, 57(1), 53–65. https://doi.org/10.1159/000546079
Hu, Q., Jin, H., Li, X., & Hu, L. (2026). Application of SGLT2 inhibitors in kidney diseases: A bibliometric analysis. Frontiers in Medicine, 13, 1768225. https://doi.org/10.3389/fmed.2026.1768225
Zheng, Y., & Sun, J. (2025). Long-term effect of sodium-glucose cotransporter 2 inhibitors in kidney functions: A systematic review and meta-analysis. Medicine, 104(7), e41422. https://doi.org/10.1097/MD.0000000000041422
Chen, X., Hocher, C. F., Shen, L., Krämer, B. K., & Hocher, B. (2023). Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: From bedside to bench. American Journal of Physiology-Cell Physiology, 325(3), C661–C681. https://doi.org/10.1152/ajpcell.00177.2023
Stankovic, S., Miloradovic, Z., Petrovic, V., & Stoiljkovic, M. (2026). Redefining SGLT2 inhibitors through cytoprotective mechanisms. European Journal of Pharmacology, 1016, 178647. https://doi.org/10.1016/j.ejphar.2026.178647
Arshad, M., Hoda, F., Siddiqui, N. A., Najmi, A. K., & Ahmad, M. (2024). Genito urinary infection and urinary tract infection in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors: Evidence from a systematic literature review of landmark randomized clinical trial. Drug Research, 74(7), 307–313. https://doi.org/10.1055/a-2347-9824
Yoosuf, B. T., Favas, M. K. T., Spoorthy, D. P., Saini, A., Garg, P., Medenica, S., Dutta, P., & Bansal, D. (2025). Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS. Endocrine, 90(2), 439–452. https://doi.org/10.1007/s12020-025-04393-7
Xu, J., Sun, A., Yang, Y., Shi, Y., Su, J., Eadon, M. T., & Zhang, P. (2025). Risk of urinary tract infections with sodium-glucose transport protein-2 inhibitors in subpopulations with abnormal genitourinary pathology. Clinical Journal of the American Society of Nephrology, 20(6), 820–828. https://doi.org/10.2215/CJN.0000000687
Yang, H., Choi, E., Park, E., Na, E., Chung, S. Y., Kim, B., & Han, S. Y. (2022). Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacology Research & Perspectives, 10(1), e00910. https://doi.org/10.1002/prp2.910
Imai, T., Kato, N., Kanda, N., Hashimoto, H., Yamana, H., & Hatakeyama, S. (2024). Risk of urogenital bacterial infection with sodium-glucose cotransporter-2 inhibitors: A retrospective cohort study using a claims database. Diabetes Therapy, 15(8), 1821–1830. https://doi.org/10.1007/s13300-024-01613-7
Confederat, L. G., Dragostin, O. M., & Condurache, M. I. (2025). SGLT2 inhibitors and the risk of urogenital infections: A concise review. Journal of Clinical Medicine, 14(6), 1960. https://doi.org/10.3390/jcm14061960
Rong, X., Zhu, Y., Wen, B., Liu, K., Li, X., Gou, Q., & Chen, X. (2022). Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 9, 973129. https://doi.org/10.3389/fcvm.2022.973129
Rong, X., Li, X., Gou, Q., & Liu, K. (2020). Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diabetes & Vascular Disease Research, 17(5), 1479164120953625. https://doi.org/10.1177/1479164120953625
Shikamura, M., Takayama, A., Yokogawa, K., & Kawakami, K. (2025). Temporal risk patterns of severe hypovolemia associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A self-controlled case series study. Diabetes, Obesity and Metabolism, 27(5), 2584–2592. https://doi.org/10.1111/dom.16259
Vukadinović, D., Abdin, A., Anker, S. D., Rosano, G. M. C., Mahfoud, F., Packer, M., Butler, J., & Böhm, M. (2022). Side effects and treatment initiation barriers of sodium-glucose cotransporter-2 inhibitors in heart failure: A systematic review and meta-analysis. European Journal of Heart Failure, 24(9), 1625–1632. https://doi.org/10.1002/ejhf.2584
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022). Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations. Kidney International Reports, 7(7), 1463–1476. https://doi.org/10.1016/j.ekir.2022.04.094
Tsai, W. C., Hsu, S. P., Chiu, Y. L., Yang, J. Y., Pai, M. F., Ko, M. J., Tu, Y. K., Hung, K. Y., Chien, K. L., Peng, Y. S., & Wu, H. Y. (2022). Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 12(10), e060655. https://doi.org/10.1136/bmjopen-2021-060655
Qiu, M., Ding, L., & Zhou, H. (2021). Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis. Medicine, 100(10), e25121. https://doi.org/10.1097/MD.0000000000025121
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St Peter, W. L. (2022). Hypoglycemia risk with SGLT2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas among Medicare insured adults with CKD in the United States. Kidney Medicine, 4(8), 100510. https://doi.org/10.1016/j.xkme.2022.100510
Lo, K. B., Gul, F., Ram, P., Kluger, A. Y., Tecson, K. M., McCullough, P. A., & Rangaswami, J. (2020). The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: A systematic review and meta-analysis. Cardiorenal Medicine, 10(1), 1–10. https://doi.org/10.1159/000503919
Di Costanzo, A., Mangione, A., Laurenti, M., et al. (2023). SGLT2 inhibitors: A new therapeutical strategy to improve renal outcomes in chronic kidney disease. International Journal of Molecular Sciences. https://doi.org/10.3390/pmc1021840
Sridharan, K., & Sivaramakrishnan, G. (2024). Risk of diabetic ketoacidosis associated with sodium glucose cotransporter-2 inhibitors: A network meta-analysis and meta-regression. Journal of Clinical Medicine, 13(6), 1748. https://doi.org/10.3390/jcm13061748
Chow, E., Clement, S., & Garg, R. (2023). Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Research & Care, 11(5), e003666. https://doi.org/10.1136/bmjdrc-2023-003666
Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., Russo, G. T., & Marini, H. R. (2024). Ketoacidosis and SGLT2 inhibitors: A narrative review. Metabolites, 14(5), 264. https://doi.org/10.3390/metabo14050264
Long, B., Lentz, S., Koyfman, A., & Gottlieb, M. (2021). Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. The American Journal of Emergency Medicine, 44, 157–160. https://doi.org/10.1016/j.ajem.2021.02.015
Zhao, Q., Tan, Y., Wu, Q., Xiao, X., Wei, X., Nian, M., Yao, J., Fan, N., Wang, R., & Fan, G. (2024). The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: A retrospective study. Expert Opinion on Drug Safety, 23(1), 57–65. https://doi.org/10.1080/14740338.2023.2275704
Gao, F. M., Kishore, K., Pandey, D., Jahanabadi, H., Stevens, M., Lecamwasam, A., Bellomo, R., Churilov, L., & Ekinci, E. I. (2025). Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy. Diabetes, Obesity and Metabolism, 27(11), 6367–6374. https://doi.org/10.1111/dom.70029
Yang, Z., Zhang, W., Chen, H., & Peng, Q. (2025). Inpatient case characteristics of SGLT2 inhibitor-associated diabetic ketoacidosis: A retrospective study. European Journal of Hospital Pharmacy, 32(6), 534–538. https://doi.org/10.1136/ejhpharm-2024-004124
Sridharan, K., & Sivaramakrishnan, G. (2025). Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: A network meta-analysis and meta-regression. Expert Opinion on Drug Safety, 24(7), 797–804. https://doi.org/10.1080/14740338.2024.2377755
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., Matthews, D. R., & CANVAS Program Collaborative Group. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England Journal of Medicine, 377(7), 644–657. https://doi.org/10.1056/NEJMoa1611925
Geng, L., Sun, B., & Chen, Y. (2024). A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations. Diabetes, Obesity and Metabolism, 26(11), 5376–5389. https://doi.org/10.1111/dom.15901
Lu, Y., & Guo, C. (2023). Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: A meta-analysis of 2 million patients. Therapeutic Advances in Drug Safety, 14, 20420986231178126. https://doi.org/10.1177/20420986231178126
Potier, L., Mohammedi, K., Velho, G., & Roussel, R. (2021). SGLT2 inhibitors and lower limb complications: The diuretic-induced hypovolemia hypothesis. Cardiovascular Diabetology, 20(1), 107. https://doi.org/10.1186/s12933-021-01301-x
Mostafa, M. E. A., & Alrasheed, T. (2024). Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A network meta-analysis of population-based cohort studies. Frontiers in Endocrinology, 15, 1410883. https://doi.org/10.3389/fendo.2024.1410883
Chou, O. H. I., Zhou, J., Satti, D. I., Lin, K., Lee, S., Wong, W. T., Wai, A. K. C., Liu, T., Cheung, B. M. Y., & Jing, F. (2023). Lower risks of new-onset hip fracture risks in users of sodium glucose cotransporter 2 (SGLT2) inhibitors versus users of dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched analysis. European Heart Journal, 44(Supplement 2), ehad655.2826. https://doi.org/10.1093/eurheartj/ehad655.2826
Dong, Z., Mo, W., Ling, Z., Hou, L., & Deng, T. (2025). Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: A meta-analysis. Journal of the National Medical Association, 117(6), 458–469. https://doi.org/10.1016/j.jnma.2025.08.110
Shi, Y., Dong, S., Xu, Y., Ji, D., Yang, L., & Zhao, R. (2024). Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: A meta-analysis of cohort studies. Acta Diabetologica, 61(6), 755–764. https://doi.org/10.1007/s00592-024-02252-x
Upadhyay, A. (2024). SGLT2 inhibitors and kidney protection: Mechanisms beyond tubuloglomerular feedback. Kidney360, 5(5), 771–782. https://doi.org/10.34067/KID.0000000000000425
Nakao, Y., Mori, M., Mori, Y., & Bonventre, J. V. (2026). SGLT2 inhibitors and acute kidney injury. Nephrology Dialysis Transplantation, 41(2), 243–254. https://doi.org/10.1093/ndt/gfaf132
Ma, Y., Lin, C., Cai, X., Hu, S., Zhu, X., Lv, F., Yang, W., & Ji, L. (2023). Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: An updated meta-analysis. Acta Diabetologica, 60(3), 435–445. https://doi.org/10.1007/s00592-022-02022-7
Brata, R., Pascalau, A. V., Fratila, O., Paul, I., Muresan, M. M., Camarasan, A., & Ilias, T. (2024). Hemodynamic effects of SGLT2 inhibitors in patients with and without diabetes mellitus: A narrative review. Healthcare, 12(23), 2464. https://doi.org/10.3390/healthcare12232464
Schumacher, C., Chorpash, A., Bolch, C., Eagan, K., Nimer, S., & Van Dril, E. (2024). Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors. Pharmacotherapy, 44(3), 249–257. https://doi.org/10.1002/phar.2902
Neuen, B. L., Fletcher, R. A., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Inzucchi, S. E., Jardine, M. J., Mahaffey, K. W., McCausland, F. R., McGuire, D. K., McMurray, J. J. V., Neal, B., Packer, M., Patel, S. M., Perkovic, V., Sabatine, M. S., Sardell, R. J., Solomon, S. D., ... SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C). (2026). SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: A meta-analysis. JAMA, 335(3), 233–244. https://doi.org/10.1001/jama.2025.20834
Li, C. X., Liu, T. T., Zhang, Q., Xie, Q., Geng, X. H., Man, C. X., Li, J. Y., Mao, X. Y., Qiao, Y., & Liu, H. (2023). Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: A meta-analysis of cohort studies. Frontiers in Pharmacology, 14, 1275060. https://doi.org/10.3389/fphar.2023.1275060
Wu, D. A., Hsu, B. G., & Lin, Y. L. (2025). Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know? Tzu Chi Medical Journal, 37(3), 255–263. https://doi.org/10.4103/tcmj.tcmj_275_24
Gorgojo-Martínez, J. J., Górriz, J. L., Cebrián-Cuenca, A., Castro Conde, A., & Velasco Arribas, M. (2024). Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: A multidisciplinary expert consensus. Journal of Clinical Medicine, 13(21), 6509. https://doi.org/10.3390/jcm13216509
Yang, S., Liu, Y., Zhang, S., Wu, F., Liu, D., Wu, Q., Zheng, H., Fan, P., & Su, N. (2023). Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 14, 1145587. https://doi.org/10.3389/fphar.2023.1145587
Talyshinskii, A., Nedbal, C., & Somani, B. K. (2026). Urological impact of flozins (SGLT2 inhibitors): An EAU Endourology review of risks, side effects and clinical considerations. Current Opinion in Urology, 36(1), 42–50. https://doi.org/10.1097/MOU.0000000000001306
Bucșa, C., Frenț, I., Stefan, R., Fodor, A., Inceu, G., Farcaș, A., Rusu, A., Negovan, M., & Mogoșan, C. (2025). Adverse drug reactions to SGLT2i reported by type 2 diabetes new users: An active surveillance study. Pharmaceuticals, 18(6), 904. https://doi.org/10.3390/ph18060904
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Julia Surowiec, Małgorzata Kawiorska, Adrianna Świerzyńska, Aleksandra Cieciora, Mateusz Cieciora, Natalia Jankowska, Aleksandra Simlat, Ilona Mariańska-Wiśniewska, Angelika Szwaj, Tomasz Puszkiel
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
